Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)

Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.

NCT Number	NCT07642557
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Chronic Spontaneous Urticaria
Enrollment	470 participants
Start Date	2026-07-10
Primary Completion	2029-05-31 (estimated)
Study Completion	2029-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-11